Use this checklist to rapid-fire your due diligence – ensure each asset in your portfolio meets critical payer evidence expectations across all ten domains.
The 10 Critical P&R Due Diligence Domains
Clinical Effectiveness
Prioritize assets with head-to-head comparator data; demonstrated superiority de-risks your portfolio against clinical uncertainty.
Health-Related Quality of Life
Favor assets with published utility data – drugs that quantify EQ-5D gains translate directly into stronger cost-effectiveness profiles.
Cost-Effectiveness
Vet assets with well-validated cost-utility models against local HTA thresholds – robust economic cases protect your returns.
Safety & Tolerability
Scrutinize long-term safety datasets – assets with few late-arising risks lower portfolio volatility.
Comparator Selection
Prioritize therapies tested against the prevailing standard of care; strong comparator evidence minimizes the need for costly follow-up studies.
Patient Population
Favor assets with comprehensive subgroup analyses – consistent efficacy across demographics de-risks global expansion.
Care Pathway Integration
Look for treatments with low operational burden – therapies that streamline into existing workflows speed adoption.
Resource Use & Budget Impact
Vet assets with documented downstream savings – therapies that free up healthcare resources bolster stakeholder support.
Evidence Quality & Robustness
Scrutinize the evidence base for bias risks – assets backed by multiple, peer-reviewed Phase III trials strengthen your confidence.
Uncertainty & Sensitivity
Prioritize assets with thorough scenario testing and clear broader-context narratives – therapies that address equity or ethical concerns carry less market risk.
See Your Edge
Run through these ten checks to identify and prioritize the highest-value, lowest-risk opportunities in your pipeline.
Do you know how your asset and the competitor’s scores in the MARA Rating?
Visit mararating.com or send us a line at sales@mararating.com.
#VentureCapital #MarketAccess #HTA #EvidenceStrategy #MARARating #MarketAccessScore